Synthesis of hydrolysis-resistant pyridoxal 5′-phosphate analogs and their biochemical and X-ray crystallographic characterization with the pyridoxal phosphatase chronophin
A set of phosphonic acid derivatives (1-4) of pyridoxal5'-phosphate (PLP) was synthesized and characterized biochemically using purified murine pyridoxalphosphatase (PDXP), also known as chronophin. The most promising compound 1 displayed primarily competitive PDXP inhibitory activity with an IC50 value of 79μM, which was in the range of the Km of the physiological substrate PLP. We also report the
[EN] CARDIOPROTECTIVE PHOSPHONATES AND MALONATES<br/>[FR] PHOSPHONATES ET MALONATES CARDIOPROTECTEURS
申请人:MEDICURE INT INC
公开号:WO2001064692A1
公开(公告)日:2001-09-07
The present invention provides for pyrodoxine phosphonate analogues such as, for example, ((2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)alkylphosphonates, and (2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)azaalkylphosphonates) and to pyridoxine malonates analogues, such as, for example, ((2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridylmethyl)malonates), pharmaceutical compositions, and methods for treatment of cardiovascular and related diseases, and diabetes mellitus and related diseases.
The present invention provides for pyridoxine phosphonate analogues such as, for example, ((2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)alkylphosphonates, and (2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)azaalkylphosphonates) and to pyridoxine malonate analogues, such as, for example, ((2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridylmethyl)malonates), pharmaceutical compositions, and methods for treatment of cardiovascular and related diseases, and diabetes mellitus and related diseases.
The present invention provides for pyrodoxine phosphonate analogues namely (2-methyl-3-hydroxy-4-hydroxymethyl-5-pyridyl)azaalkylphosphonates), pharmaceutical compositions, and uses thereof for treatment of cardiovascular and related diseases, and diabetes mellitus and related diseases.